UNIVERSITY OF BIRMINGHAM

EURO EWING Consortium EEC

@CRCTU Cancer Research UK Clinical Trials Unit

7th rEECur Newsletter

Issue 7

rEECur@trials.bham.ac.uk

30th November 2020

TRIAL UPDATE

Welcome to the 7th rEECur newsletter. Since our last newsletter we have three major milestones to celebrate;

1. We dropped our second arm Irinotecan & Temozolomide (IT) in March 2020.
2. The 400th patient was recruited on 18th June 2020.
3. We have introduced the first new arm into the study: Carboplatin and Etoposide.

We now have **428** patients in the study, and have even continued to recruit over 4 patients per month on average since the start of the pandemic. Well done to everyone for this amazing effort! Please remember, about one fifth of all patients are recruited from centres with only 1 or 2 recruits. Every patient recruited contributes to the study and is really important.



Recruitment by Country



Top 6 Recruiting Sites	No of PTS
Hospital Virgen Del Rocio, Spain	27
Istituto Ortopedico Rizzoli, Italy	22
University College London Hospital, UK	19
Centre Leon Berard, France	13
Hospital Politecnico U La Fe, Spain	13

Using the MAMS Design

A major strength of rEECur's design is our ability to bring in and drop treatment arms while continuing to recruit to the most effective arms. We have now brought in a carboplatin and etoposide arm. This is the last new chemotherapy arm we plan to study, but we hope to bring in two additional targeted therapy drugs in the near future – more details to come. The new arm is through its regulatory stages in the UK and will be opening soon. International sites are now submitting the amended protocol for regulatory approval.

Publications and Presentations

An abstract describing the outcomes of patients recruited to the GD arm, which closed to recruitment in 2018, was presented to ASCO in 2019 and a paper is planned for submission in 2021.

The IT arm closed to recruitment following the planned interim analysis held earlier this year. The data monitoring committee made their recommendation on the basis that IT was not as promising as the other treatment arms based on response and progression-free survival. There were no safety concerns. The results were presented to ASCO 2020 and a paper is planned when all patients recruited to IT have mature follow up.

CRCTU Working From Home

IMPORTANT

We are now operating a mixed model of home and office working during the COVID-19 pandemic . **Please do not contact our usual office/landline number and instead continue to email the rEECur trial mailbox.**

Please review all AEs experienced by trial patients. Adverse Reactions should be reported on the Treatment Form for the relevant cycle. AEs that meet the definition of an SAE should be reported to the rEECur Trial Office within 24 hours upon becoming aware of the event. Please do not send any faxes for SAE reporting – these must be emailed to reg@trials.bham.ac.uk

Contact the rEECur Trial Team

Office hours 09:00-17:00 GMT, Monday-Friday ✉ **reecur@trials.bham.ac.uk**